Evotec’s Post

This year's Meeting on the Mesa was on 🔥 🔥 🔥 ! I’m thinking back to some key themes about democratizing access to cell and gene therapies from this year’s Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa. The promise of decentralized & point-of-care manufacturing: it’ll require shorter manufacturing times but recent advances suggest that it could be feasible soon. Great progress towards this goal from the lab of Saba Ghassemi, Ph.D., and organizations such as Kyverna Therapeutics, Novartis, Germfree, & Caring Cross The rise of nonviral workflows: these may be safer, more cost-effective, and require less QC and characterization. Solutions from CellFE, Kytopen, MaxCyte, Inc., & Thermo Fisher Scientific come to mind. I’d also like to thank everyone who met with the xcellbio team during partnering sessions at the conference. We developed our AVATAR suite of instruments to help scientists deliver higher-performing cell therapies and we’re excited to team up with more pharma and biotech companies to make that happen! #curecancer #curecancer #avatarfoundry #enhancepotency #cellandgenetherapy #tumormicroenvironment #celltherapymanufacturing Visit us at xcellbio.com/gmp to learn how we manufacture more potent cell therapies

I've been following Fierce Biotech's answer to 'March Madness', the #fiercemadness 'Best Biotech Name Tournament' and rooting for Obsidian Therapeutics. Although they do sound like a special ops task force, they are named after the volcanic glass used for making sharp, precise blades to which they liken their approach to creating cell & gene therapies. Here's the final 8: Werewolf Therapeutics | Orca Bio | Moonwalk Biosciences | Rain Oncology | Viking Therapeutics, Inc. | ProfoundBio | Jazz Pharmaceuticals | Ampersand Biomedicines

To discuss how to de-risk your viral vector prior to clinical trials, please reach out to our team at #ISCT2024 in Vancouver. Farzin Farzaneh, PhD Traci Kyes Makis Sigalas

This is a particularly interesting fireside chat. Looking forward to seeing John & Chris discuss the Autolus Therapeutics journey at #ATE24!

“When we first started working together, nobody was interested in RNA. We couldn't get funding. We couldn't get papers published. But we saw the potential and we saw enormous potential, and as we were doing our work, the data kept supporting an enormous potential.” And thank goodness they did! This week’s #SciencEE features Drew Weissman, MD, PhD, 2023 The Nobel Prize in Medicine! Famously known for his groundbreaking, nobel-prize winning work in #mRNA science, Dr. Weissman joined our recent scientific symposium to discuss the potential of lipid nanoparticles to deliver gene editing therapies to treat #cysticfibrosis. Thank you to our 2024 #CFAwarenessMonth Tier 2 sponsors — Boehringer Ingelheim, Viatris, 4D Molecular Therapeutics, ReCode Therapeutics, Baxter International Inc. and Enterprise Therapeutics — for supporting our #SciencEE series! #CrossOutCF #CFAwarenessMonth #CFAwareness #CysticFibrosis Penn Medicine, University of Pennsylvania Health System

If you're excited for a fantastic science meal at #ESGCT2024 in #Rome, don't forget to save room for dessert! Peter Cabeceiras will give an oral presentation during the last session of the ESGCT meeting on DLVR-M a novel virus-like particle developed at Nvelop Therapeutics We will share our preliminary data showing that this particle can be fully humanized, can accommodate a variety of editing cargos for #invivo #genetherapy, including #CRISPR Base and Prime editors, and can achieve high efficiency of multiplex #geneediting in therapeutic relevant loci in resting #hematopoietic #stemcells. Title: DLVR-M: a novel fully humanized particle for the efficient in vivo delivery of large gene-editing cargoes to human cells. Date/Time: Friday, October 25, 11:00 a.m. – 1:00 p.m. CEST Abstract #OR106 Session room: Meeting room 2 See you there!!

What is top of mind across cell therapy?... While ISCT, International Society for Cell & Gene Therapy annual meeting is in the rearview, the highlights, key trends, and hurdles remain! We asked stakeholders from companies like Ori Biotech, xcellbio, and uBriGene Biosciences Inc., and investors from AVANT BIO what their key takeaways are. Check it out here: 👉 https://lnkd.in/dEUWbKAi The long and short, you ask? 1️⃣ Manufacturing Innovations and Challenges: The field is rapidly advancing with new automated platforms to address current suboptimal workflows. 2️⃣ Technological Advancements and Excitement: The conference saw multiple launches of new systems, like Ori's IRO®, Cytiva's enhanced Sefia system, and Xcellbio's AVATAR. 3️⃣ Focus on Potency and Data-Driven Processes: There was a strong emphasis on developing better potency assessments and leveraging data-driven processes. Did you attend the conference? What was your key takeaway? Let me know! #celltherapy #pharma #healthcare

How can we address the hurdles limiting scalable viral vector manufacturing for cell and gene therapy? A new international consortium has £1.1M funding for a fresh approach. Abselion is delighted to be joining VVector Bio, the National Research Council Canada / Conseil national de recherches Canada, and Revvity to apply a multifaceted strategy to unlock viral vector production capabilities. Jointly funded by Innovate UK and the NRC, as part of the Biomanufacturing of Biologics and Advanced Therapies programme, the project will combine detailed multi-omics analysis of the HEK-293 cell line with a new approach to manufacturing and process monitoring empowered by at-line and on-line process analytics.   The project seeks to develop the next-generation cell platform for viral vector production, improving yields, quality, scalability and lowering costs, to ultimately help to accelerate the creation of therapies for patients. Learn more: https://lnkd.in/eY6CrTej #genetherapy, #celltherapy, #bioprocessing, #drugdevelopment #genomics

🚨Just two days away... Have you factored in mitigating innate antiviral defenses into your scale-up model? Deciding whether to scale up or out your cell therapy process? Our experts Andrea Vervoort, Jondavid de Jong, & Jean-Simon Diallo will cover all you need to know about antiviral defenses and present how Virica uses bioprocess modeling to evaluate the benefits of enhancing technologies such as our Viral Sensitizer (VSE) platform by observing key cost drivers and identifying how they are influenced by even modest improvements in yield. Expect to learn: -The impact of innate antiviral defenses on viral vector yield and quality -An overview of the mode of action and benefits of VSEs -A case study demonstrating how VSEs can enhance AAV yield and scale-up efficiency. -Employing bioprocess modeling to determine long-term cost benefits of VSE-mediated enhancement of AAV in HEK293 cells. The webinar will be hosted with our partner BioInsights (Cell and Gene Insights) on Jan 25, 2024; 11:00 EST, 8:00 PST, 16:00GMT, 17:00 CET. Register: https://lnkd.in/ez5Euymk

Our very own Principal Scientist, Daniel Miller is the featured expert in EditCo Bio’s upcoming webinar: AI-driven identification and validation of novel synthetic lethal gene pairs.  The webinar will discuss how Evariste leverages AI to accelerate drug discovery, utilizing EditCo's CRISPR Express Cell Pools and Arctoris' Ulysses® to drive rapid target validation. Topics covered include: 🔬 Synthetic lethality (SL) as a promising, untapped oncology strategy, with currently limited actionable targets. 🔍 How Evariste uses Frobenius Target to identify novel SL gene pairs and validates them using high-throughput CRISPR editing and robotic cell biology assays. 💡 Case study on a novel SL pair involving the oncology target FAK, showcasing the platform’s ability to identify a pipeline of clinically actionable targets. Danny will be joined by industry leaders Travis Hardcastle from EditCo and Kinga Bercsenyi from Arctoris. Their expertise, combined with Danny's insights, will make this a must-attend webinar! 🗓️ Date: 18th July, 12:00 EST 📝 Register now: https://lnkd.in/ePREsEJX #Evariste #EditCo #Arctoris #AIDrugDiscovery #SyntheticLethality #TechBio #CRISPR